


Journal Pre-proof



Long-term outcomes of a course of deep TMS for treatment-resistant OCD

Tal Harmelech, Aron Tendler, Mehmet Kemal Arikan, Hamide Laçin Çetin, Muhammed Taha Esmeray, Reyhan Ilhan, Ryan Vidrine, Owen Muir, Carlene MacMillan, Rebecca Sinclair, Saad Shakir, David Kent, Nicholas Evangelidis, Yiftach Roth

PII: S1935-861X(21)00846-9

DOI: <https://doi.org/10.1016/j.brs.2021.12.011>

Reference: BRS 2107

To appear in: *Brain Stimulation*

Received Date: 30 November 2021

Revised Date: 29 December 2021

Accepted Date: 30 December 2021

Please cite this article as: Harmelech T, Tendler A, Arikan MK, Çetin HamideLaç, Esmeray MT, Ilhan R, Vidrine R, Muir O, MacMillan C, Sinclair R, Shakir S, Kent D, Evangelidis N, Roth Y, Long-term outcomes of a course of deep TMS for treatment-resistant OCD, *Brain Stimulation* (2022), doi: <https://doi.org/10.1016/j.brs.2021.12.011>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc.

Title: Long-term outcomes of a course of Deep TMS for treatment-resistant OCD

Author names and affiliations:

Tal Harmelech^{1*}, Aron Tendler^{1,2,3}, Mehmet Kemal Arikan⁴, Hamide Laçın Çetin⁴, Muhammed Taha Esmeray⁴, Reyhan İlhan⁴, Ryan Vidrine⁵, Owen Muir⁶, Carlene MacMillan⁶, Rebecca Sinclair⁶, Saad Shakir⁷, David Kent⁸, Nicholas Evangelidis⁹, Yiftach Roth^{1,3}

¹BrainsWay Ltd. 19 Hartum St. Har Hotzvim Jerusalem 9777518 Israel

²Advanced Mental Health Care Inc., 1903 Southern Blvd. Royal Palm Beach, FL 33411, USA

³Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben Gurion University of the Negev, Beer Sheva, Israel

⁴Akademik Psychiatry & Psychotherapy Center Halaskargazi Cad. No: 103, Gün Apt, apartment: 4B 34371 Osmanbey – Istanbul, Turkey

⁵Mindful Health Solutions, 360 Post Street, suite #500, San Francisco, CA, 94108, USA

⁶Brooklyn Minds, 347 Grand St, Brooklyn, NY, 11211, USA

⁷Silicon Valley TMS, 2039 Forest Ave Esthetician Freshman Classroom, San Jose, CA, 95128, USA

⁸NuMe TMS, 2375 S Cobalt Point Way #102, Meridian, ID, 83642, USA

⁹Katie's Way, 720 Poyntz Avenue, Manhattan, KS, 66502, USA

Corresponding author: Tal Harmelech (tal.harmelech@brainsway.com)

After a multicenter randomized sham-controlled trial of Deep TMS™ therapy for obsessive-compulsive disorder (OCD) demonstrated a 38% response rate that is sustained for at least four weeks¹ the FDA granted a de novo clearance for the H7 Coil. In real-world clinical practice settings 52.4% of patients achieved at least one month sustained response².

There have been limited studies on the durability of pharmacotherapy for OCD and the few publications on the subject report no durability, requiring maintenance³⁻⁴. With regards to cognitive behavioral therapy (CBT), there are mixed results. A recent large meta-analysis of twenty-four randomized controlled trials demonstrated no durability⁵. Another study found durability after one year⁶. Yet another study demonstrated durability for a year for patients who reached remission (Y-BOCS score ≤ 12), while patients with higher post-treatment Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) scores had a high likelihood of decompensating. In adolescent OCD durability of up to 3 years has been reported for CBT⁸. No durability is reported for DBS since turning off the stimulator results in immediate symptom worsening⁹.

To shed some light on the potential durability of Deep TMS treatment for OCD, clinical sites that participated in the OCD multicenter trial as well as those that contributed the post marketing data were contacted (n=16). All sites were provided with a list of their patients who met response criteria at their last Y-BOCS evaluation following the Deep TMS treatment course (overall N=108) and were compensated for contacting these patients and reporting whether each of them had, since the end of their treatment, any medication change/CBT/hospitalization/Deep TMS re-treatment. If so, on what date did the change in treatment occur and was it due to an exacerbation of the patient's OCD or due to a desire for greater improvement. Sites were also requested to inquire about functional disability, days lost and days unproductive per week. The patient populations were previously described¹⁻², and the study was approved by Sterling Institutional Review Board.

The potential durability of response to Deep TMS was defined as the elapsed time from the end of the Deep TMS treatment course until a change in treatment occurred. Demographic data on the participating patients had already been recorded prior to their Deep TMS treatment course

and included the following information: OCD symptom severity (Y-BOCS), functional impairment (Sheehan Disability Scale, SDS), comorbidities, age, gender, age of OCD onset, family history of OCD, number of life-time failed medications, and concomitant SRI medications. Symptom severity (Y-BOCS) had also been recorded at the end of each patient's Deep TMS treatment course as well as the number of Deep TMS sessions they received. This data allowed, beyond reporting on the average 'durability' of Deep TMS treatment for OCD, an analysis of predictors and moderators of the Deep TMS response "durability".

The analysis set included 60 patients from 7 centers for whom there was 'durability' data. Of those, only 8 patients (13.3%) had 'durability' of <1 year, while 52 patients (86.7%) had 'durability' of ≥ 1 year. Half of the patients who had at least 1 year 'durability' ($n=26$), who represent 43.3% of the analysis set, had 'durability' of ≥ 2 years (Figure 1B). The average 'durability' of Deep TMS for OCD was $\geq 1.98(\pm 0.13)$ years. Importantly, 37/60 (62%) patients were still considered to have Deep TMS 'durability' at the time of the survey (see Figure 1A for a narrative breakdown of the data). None of the demographic or treatment information was found to be predictive of 'durability' length.

Almost half of the analysis set ($n=28$) had functional disability data (SDS) as well. A significant reduction in disability was reported by patients following Deep TMS treatment. While prior to Deep TMS the self-reported unproductive days per week was on average $5.5(\pm 0.4)$, post treatment it was only $1.8(\pm 0.4)$ – an average reduction of $3.8(\pm 0.4)$; $p < 5^{-9}$). The decrease in lost days per week was also statistically significant, with reports of an average of $1.9(\pm 0.6)$ prior to Deep TMS vs. $0.3(\pm 0.2)$ post treatment – an average reduction of $1.8(\pm 0.5)$; $p < 0.001$ (Figure 1C). A significant correlation was found between the improvement in symptom severity (i.e., reduction in Y-BOCS from baseline) to the functional improvement (i.e., reduction in weekly unproductive days) following Deep TMS treatment ($r=0.45$, $p=0.018$) (Figure 1D).

It has been previously demonstrated that Deep TMS therapy is an effective treatment for OCD patients who have failed multiple medications¹⁰, alluding to a different mechanism of action. The 'durability' results demonstrated here reaffirm that the mechanism of Deep TMS treatment in OCD is different from that of medications that necessitate chronic use. The mechanism of Deep

TMS is likely based on direct modulation of the cortical-striatal-thalamic-cortical circuitry, specifically through up-regulation of the Anterior Cingulate Cortex (ACC)^{1,11}. A recent 1H-MRS study found significant increases in levels of NAA, Choline and Creatine in the ACC following Deep TMS in OCD patients, indicating direct neural stimulation of this region¹². A recent modelling study found that Deep TMS induces significant electric field in various deep structures including the ACC¹³.

As with any registry-based study, the primary limitations to ours are incomplete data due to a lack of follow up or continued care with the Deep TMS provider after the treatment course. Many patients only went to the Deep TMS center for the treatment and not their ongoing psychiatric care, which limited the analysis set to 60/108 responders and 7/16 centers. Furthermore, as the Y-BOCS is not used in routine clinical practice, this resulted in a 'durability' definition as elapsed time from the last Deep TMS session until any change in treatment was necessary. Ideally, this would be corroborated by Y-BOCS scores, a more standardized metric administered every few months. Confirmatory and mechanistic studies investigating the response 'durability' of Deep TMS therapy for OCD with standardized measures are warranted.

Figure 1. 'Durability' of Response and Functional Disability following Deep TMS™ for Treatment-Resistant OCD. (A) CONSORT flow diagram presenting a narrative breakdown of the available data. (B) Kaplan-Meier survival curve of cumulative 'durability' of response to Deep TMS for OCD, where 'durability' is defined as time since Deep TMS without change in treatment for patients who met response criteria at their last Y-BOCS evaluation after the Deep TMS course. (C) Functional disability presented as days lost (grey bars) and days unproductive (blue bars) per week pre and post Deep TMS (left and right, respectively). Asterisks denote statistical significance: *-p<0.001, **-p<5⁻⁹. (D) Scatter plot presenting correlation across patients between change from baseline in functional disability (weekly unproductive days) and in symptom severity (Y-BOCS score) following Deep TMS.

Funding: BrainsWay Ltd.


Potential conflicts of interest: Tal Harmelech is a BrainsWay employee. Aron Tendler is the Chief Medical Officer of BrainsWay and has a financial interest in BrainsWay as well as a commercial clinical and research TMS center. He has received speaking fees from BrainsWay, Neuronetics

and the Clinical TMS Society. Yiftach Roth is a key inventor of the Deep TMS technology, Chief Scientist at BrainsWay and has a financial interest in BrainsWay.

References

1. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *American Journal of Psychiatry* 2019, appi.ajp.2019.1. doi:10.1176/appi.ajp.2019.1810
2. Roth Y, Tendler A, Arikian MK, et al. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites. *Journal of Psychiatric Research* 2021, 137:667-672. <https://doi.org/10.1016/j.jpsychires.2020.11.009>.
3. Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. *American Journal of Psychiatry* 1988, 145(12):1521-1525. <http://doi.org/10.1176/ajp.145.12.1521>.
4. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. *Archives of General Psychiatry* 1991, 48(10):922. doi: 10.1001/archpsych.1991.0181.
5. Fisher PL, Cherry MG, Stuart T, et al. People with obsessive-compulsive disorder often remain symptomatic following psychological treatment: A clinical significance analysis of manualised psychological interventions. *Journal of Affective Disorders* 2020, 275:94-108. <https://doi.org/10.1016/j.jad.2020.06.019>.
6. Nadeem MJ, Chan E, Drummond L. A Naturalistic Study of the Maintenance of Gains Made With Treatment of Patients With Profound Treatment-Refractory Obsessive-Compulsive Disorder. *Frontiers in Psychiatry* 2021, 12:1209. <https://doi.org/10.3389/fpsy.2021.673390>.
7. Elsner B, Wolfsberger F, Srp J, et al. Long-Term Stability of Benefits of Cognitive Behavioral Therapy for Obsessive Compulsive Disorder Depends on Symptom Remission During Treatment. *Clinical Psychology in Europe* 2020, 2(1):1-18. <https://doi.org/10.32872/cpe.v2i1.2785>
8. Melin K, Skarphedinsson G, Thomsen PH, et al. Treatment Gains Are Sustainable in Pediatric Obsessive-Compulsive Disorder: Three-Year Follow-Up From the NordLOTS. *J Am Acad Child Adolesc Psychiatry* 2020, 59(2):244-253. doi: 10.1016/j.jaac.2019.01.010. Epub 2019 Feb 14. PMID: 30768383.
9. de Koning P, Figee M, Endert E, et al. Rapid effects of deep brain stimulation reactivation on symptoms and neuroendocrine parameters in obsessive-compulsive disorder. *Transl Psychiatry* 2016, 6:e722. <https://doi.org/10.1038/tp.2015.222>
10. Roth Y, Barnea-Ygaël N, Carmi L, et al. Deep transcranial magnetic stimulation for obsessive-compulsive disorder is efficacious even in patients who failed multiple medications and CBT. *Psychiatry Research* 2020. 290:113179, <https://doi.org/10.1016/j.psychres.2020.113179>.

11. Carmi L, Alyagon U, Barnea-Ygael N, et al. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. *Brain Stimul* 2018. 11 (1), 158–165.
12. Reddy S, Goyal N, Shreekantiah U. Adjunctive deep transcranial magnetic stimulation (dTMS) in obsessive compulsive disorder: Findings from 1 H magnetic resonance spectroscopy. *Asian Journal of Psychiatry* 2021, 62:102721.
13. Gomez-Tames J, Hamasaka A, Hirata A, et al. Group-level analysis of induced electric field in deep brain regions by different TMS coils. *Phys Med Biol* 2020, 65:025007.



We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Tal Harmelech is a BrainsWay employee. Aron Tendler is the chief medical officer of BrainsWay and has a financial interest in BrainsWay as well as a commercial clinical and research TMS center. He has received speaking fees from BrainsWay, Neuronetics and the Clinical TMS Society. Yiftach Roth is a key inventor of the Deep TMS technology, chief scientist at BrainsWay and has a financial interest in BrainsWay.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (tal.harmelech@brainsway.com).

Signed by all authors as follows:

Tal Harmelech

Aron Tendler


Mehmet Kemal Arikan

Hamide Laçın Çetin

Muhammed Taha Esmeray

Reyhan Ilhan

Ryan Vidrine



Owen Muir



Carlene MacMillan



Rebecca Sinclair

Rebecca Abbott-Sinclair


Saad Shakir

Saad A. Shakir, MD

David Kent



Nicholas Evangelidis



Yiftach Roth

